Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291142 | 0.88 | MAP3K5 (0.45) | MAP3K5CYP11B1CYP11B2LRRK2APP | |
| SCHEMBL2289469 | 0.79 | MAPT (0.44) | TP53GAAMAPTSMN1; SMN2 | |
| SCHEMBL28842738 | 0.76 | MAP3K5 (0.52) | MAP3K5CYP11B1CYP11B2LRRK2APP | |
| SCHEMBL2291165 | 0.75 | MAPT (0.41) | SRCTP53GAAMAPTSMN1; SMN2 | |
| SCHEMBL2285933 | 0.70 | NPC1 (0.45) | TP53GAAMAPTSMN1; SMN2 | |
| SCHEMBL14427902 | 0.70 | CYP11B1 (0.57) | MAP3K5CYP11B1CYP11B2APPALDH1A3 | |
| SCHEMBL2291938 | 0.69 | MAPT (0.38) | TP53GAAMAPTSMN1; SMN2 | |
| SCHEMBL2295452 | 0.65 | SRC (0.44) | SRCTP53GAAMAPTSMN1; SMN2 | |
| SCHEMBL1318544 | 0.65 | MAP3K5 (0.61) | MAP3K5LRRK2ABL1 | |
| SCHEMBL14647252 | 0.65 | MAP3K5 (0.54) | MAP3K5CYP11B1CYP11B2LRRK2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | GLP1R, SLC5A1, SLC5A2 | MAP3K5 1158/4885CYP11B1 2023/4885CYP11B2 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.